Trial Outcomes & Findings for Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy (NCT NCT00962429)
NCT ID: NCT00962429
Last Updated: 2020-08-19
Results Overview
COMPLETED
PHASE2
7 participants
16 weeks
2020-08-19
Participant Flow
The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available.
Participant milestones
| Measure |
Lipoic Acid
alpha lipoic acid
lipoic acid: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
|
Placebo
sugar pill
lipoic acid: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 16 weeksPopulation: The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 16 weeksPopulation: The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 16 weeksPopulation: The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 16 weeksPopulation: The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available.
Outcome measures
Outcome data not reported
Adverse Events
Lipoic Acid
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place